Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | GABRE | P78334 | 1/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31423772 | 1.00 | LMNA (0.56) | LMNACASP6TSHRHCAR3ALDH1A1 | |
| SCHEMBL31423773 | 1.00 | LMNA (0.56) | LMNACASP6TSHRHCAR3ALDH1A1 | |
| SCHEMBL31423765 | 0.86 | PARP1 (0.50) | LMNACASP6TSHRALDH1A1TDP1 | |
| SCHEMBL4170811 | 0.86 | PARP1 (0.50) | LMNACASP6TSHRALDH1A1TDP1 | |
| SCHEMBL2303103 | 0.85 | LMNA (0.42) | LMNACASP6TSHRALDH1A1 | |
| SCHEMBL2668265 | 0.84 | LMNA (0.43) | LMNATSHRALDH1A1GABRPGABRD | |
| SCHEMBL27488036 | 0.82 | LMNA (0.41) | LMNACASP6TSHRHCAR3ALDH1A1 | |
| SCHEMBL5248286 | 0.81 | MAPK1 (0.56) | ALDH1A1TPMTKDM4EMEN1KMT2A | |
| SCHEMBL2637045 | 0.81 | CASP6 (0.53) | LMNACASP6TSHRHCAR3ALDH1A1 | |
| SCHEMBL27986105 | 0.80 | TSHR (0.49) | LMNACASP6TSHRHCAR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530294-B | Aryl diamine immobilized linker, precursor thereof, preparation method and application | 浙江大学 | 2025-02-14 | — | — | CN | disclosed |
| CN-119410629-A | Method for synthesizing cyclic peptide nucleic acid by one-pot method and cyclic peptide nucleic acid | 浙江大学 | 2025-02-11 | — | — | CN | disclosed |
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | UNIVERSITE DE MONTREAL (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | UNIVERSITE DE MONTREAL (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | UNIVERSITE DE MONTREAL (CA) | 2016-10-13 | — | — | US | disclosed |
| EP-2350073-B1 | 3H-IMIDAZO[4,5-b]PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-8703796-B2 | 3H-imidazo [4, 5-B] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| EP-1940837-B1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120115902-A1 | 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-6573274-B1 | Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| US-20020193398-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
| WO-2002064211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| EP-1124822-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1136492-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | disclosed |
| EP-1124822-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | LMNA 1751/4885CASP6 4038/4885TSHR 587/4885 |
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MC4R, MC5R, MC1R | LMNA 4580/4885CASP6 4806/4885TSHR 38/4885 |
| US-20020193398-A1 | Thrombin inhibitors | F2, F3, TFPI | LMNA 1368/4885CASP6 462/4885TSHR 145/4885 |
| US-20120115902-A1 | 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | MAP4, MAPRE2, IL4 | LMNA 3024/4885CASP6 701/4885TSHR 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.